interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Docetaxel

Generic competition · all medicines · read 12 November 2026

Is there a generic of Docetaxel, and who makes it?

Docetaxel appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 10 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 18.5 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Docetaxel2 dosage-form groups in the Orange Book
10generic makers listed
  1. Docetaxel appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 10 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 18.5 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Injectable, Injection

Four or more generic makers listed

Brand listed as marketed: Docetaxel and Taxotere. 10 generic makers with 29 generic products listed as marketed; the first generic approval is dated 5 November 2014.

199520002005201020152020202520302035010brand 1996Dr Reddys Laboratories Ltd, first approval 5 November 2014Jiangsu Hengrui Pharmaceuticals Co Ltd, first approval 9 August 2017Amneal Eu Ltd, first approval 19 January 2018Mylan Laboratories Ltd, first approval 30 April 2018Meitheal Pharmaceuticals Inc, first approval 24 August 2018Adaptis Pharma Private Ltd, first approval 16 May 2019Hikma Farmaceutica Portugal Sa, first approval 14 January 2021Gland Pharma Ltd, first approval 1 July 2021Alembic Pharmaceuticals Ltd, first approval 28 February 2023Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc, first approval 28 February 2024data datePatent 10842770 listed to expire 7 August 2031Patent 9763880 listed to expire 30 September 2033Patent 8940786 listed to expire 30 September 2033Patent 9308195 listed to expire 30 September 2033
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Dr Reddys Laboratories Ltd5 November 20142
Jiangsu Hengrui Pharmaceuticals Co Ltd9 August 20173
Amneal Eu Ltd19 January 20183
Mylan Laboratories Ltd30 April 20184
Meitheal Pharmaceuticals Inc24 August 20183
Adaptis Pharma Private Ltd16 May 20193
Hikma Farmaceutica Portugal Sa14 January 20212
Gland Pharma Ltd1 July 20213
Alembic Pharmaceuticals Ltd28 February 20233
Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc28 February 20243

Patents and exclusivities still listed

  • 7 August 2031Patent 10842770 drug product
  • 30 September 2033Patent 9763880
  • 30 September 2033Patent 8940786 drug product
  • 30 September 2033Patent 9308195 drug product

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Beizray and Docivyx. No generic is listed as marketed.

2020202520302035204001brand 2022data datePatent 10398785 listed to expire 14 March 2036Patent 12090134 listed to expire 16 May 2036Patent 11419842 listed to expire 16 May 2036Patent 12090135 listed to expire 16 May 2036
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 14 March 2036Patent 10398785 drug product
  • 16 May 2036Patent 12090134 drug product
  • 16 May 2036Patent 11419842 drug product
  • 16 May 2036Patent 12090135 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.